Therapies used in prostate cancer patients by european urologists: Data on indication with a focus on expectations, perceived barriers and guideline compliance related to the use of bisphosphonates

Urologia Internationalis

Volumn 89, Issue 1, 2012, Pages 30-38

  Heidenreich, Axel ^a   Witjes, Wim P J ^b   Bjerklund Johansen, Truls E ^c   Patel, Anup ^d  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b AKZO NOBEL CENTRAL RESEARCH   (Netherlands)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d ST MARY S HOSPITAL   (United Kingdom)

Author keywords

Androgen deprivation; Bone metastasis; Castration resistant prostate cancer; Clodronate; Europe; Ibandronate; Osteonecrosis of the jaw; Renal insufficiency; Zoledronic acid

Indexed keywords

ANALGESIC AGENT; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; GONADORELIN DERIVATIVE;

ANDROGEN DEPRIVATION THERAPY; ARTICLE; ASYMPTOMATIC DISEASE; BONE METASTASIS; BONE PAIN; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CASTRATION RESISTANT PROSTATE CANCER; HEALTH SURVEY; HUMAN; INTERNET; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE CANCER; QUESTIONNAIRE; TREATMENT INDICATION;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; ATTITUDE OF HEALTH PERSONNEL; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; DIPHOSPHONATES; EUROPE; GUIDELINE ADHERENCE; HEALTH CARE SURVEYS; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; INTERNET; MALE; NEOPLASM STAGING; PALLIATIVE CARE; PATIENT SELECTION; PERCEPTION; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; PROSTATIC NEOPLASMS; QUESTIONNAIRES; RISK ASSESSMENT; RISK FACTORS; UROLOGY;

EID: 84864615266     PISSN: 00421138     EISSN: 14230399     Source Type: Journal    
DOI: 10.1159/000338810     Document Type: Article

References (29)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ: Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96. (Pubitemid 351521864)
2. Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP, Zattoni F, European Association of Urology. EAU guidelines on prostate cancer. Eur Urol 2008; 53: 68-80. (Pubitemid 350166735)
3. Weinfurth KP, Li Y, Castel LD, et al: The significance of skeletal-related events for the health related quality of life of patients with metastatic prostate cancer. Ann Oncol 2005; 16: 579-584. (Pubitemid 40613323)
4. Saad F, Lipton A, Cook R, Chen YM, Smith M, Coleman R: Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer 2007; 110: 1860-1867. (Pubitemid 47557312)
5. Janjan N: Bone metastases: approaches to management. Semin Oncol 2001; 28(suppl 11):28-34. (Pubitemid 32844926)
6. Yau V, Chow E, Davis L, et al: Pain management in cancer patients with bone metastases remains a challenge. J Pain Symptom Manage 2004; 27:1-3. (Pubitemid 38050241)
7. Miaskowski C, Dodd MJ, West C, Paul SM, Tripathy D, Koo P, Schumacher K: Lack of adherence with the analgesic regime: a significant barrier to effective cancer pain management. J Clin Oncol 2001; 19: 4275-4279. (Pubitemid 33096774)
8. Mundy GR: Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002; 2: 584-593. (Pubitemid 37328925)
9. Saad F, Gleason DM, Murray R, et al: A randomized, placebo-controlled trial of zole-dronic acid in patients w it h hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94: 1458-1468.
10. Nørgaard M, Jensen AØ, Jacobsen JB, Cetin K, Fryzek JP, Sørensen HT: Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). J Urol 2010; 184: 162-167.
11. Lipton A: Implications of bone metastases and the benefits of bone-targeted therapy. Semin Oncol 2010; 37(suppl 2):S15-S29.
12. Dearnaley DP, Mason MD, Parmar MK, Sanders K, Sydes MR: Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and MRC PR05 randomised controlled trials. Lancet Oncol 2009; 10:872-876.
13. Heidenreich A, Elert A, Hofmann R: Iban-dronate in the treatment of prostate cancer associated painful osseous metastases. Prostate Cancer Prostatic Dis 2002; 5: 231-235.
14. Small EJ, Smith MR, Seaman JJ, Petrone S, Kowalski MO: Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with met-astatic prostate cancer. J Clin Oncol 2003; 21: 4277-4284. (Pubitemid 46621802)
15. O'Rourke N, McCloskey E, Houghton F, Huss H, Kanis JA: Double-blind, placebo-controlled, dose-response trial of oral clo-dronate in patients with bone metastases. J Clin Oncol 1995; 13: 929-934.
16. Ernst DS, MacDonald RN, Paterson AH, Jensen J, Brasher P, Bruera E: A double-blind, crossover trial of intravenous clodronate in metastatic bone pain. J Pain Symptom Manage 1992; 7:4-11.
17. Heidenreich A, Hofmann R, Engelmann UH: The use of bisphosphonates for the palliative treatment of painful bone metastasis due to hormone refractory prostate cancer. J Urol 2001; 165: 136-140.
18. Gálvez R, Ribera V, González-Escalada JR, Souto A, Cánovas ML, Castro A, Herrero B, de Los Angeles Maqueda M, Castilforte M, Marco-Martínez JJ, Pérez C, Vicente-Fatela L, Md CN, Orduña MJ, Padrol A, Reig E, Carballido J, Cózar JM: Analgesic efficacy of zoledronic acid and its effect on functional status of prostate cancer patients with metastasis. Patient Prefer Adherence 2008; 2:215-224.
19. TM: Prostate Cancer. www.nccn.org/profession-als/physician- gls/PDF/prostate.pdf.
20. British Association of Urological Surgeons. Metastatic prostate cancer guidelines. www. echurology.co.uk/baus.html.
21. Alibhai SM, Duong-Hua M, Cheung AM, Sutradhar R, Warde P, Fleshner NE, Paszat L: Fracture types and risk factors in men with prostate cancer on androgen deprivation therapy: a matched cohort study of 19,079 men. J Urol 2010; 184: 918-923.
22. Saylor PJ, Kaufman DS, Michaelson MD, Lee RJ, Smith MR: Application of a fracture risk algorithm to men treated with androgen deprivation therapy for prostate cancer. J Urol 2010; 183: 2200-2205.
23. Campbell SC, Bhoopalam N, Moritz TE, Pandya M, Iyer P, Vanveldhuizen P, Ellis NK, Thottapurathu L, Garewal H, Warren SR, Friedman N, Reda DJ: The use of zoledronic acid in men receiving androgen deprivation therapy for prostate cancer with severe os-teopenia or osteoporosis. Urolog y 2010; 75: 1138-1143.
24. Ryan CW, Huo D, Demers LM, Beer TM, Lacerna LV: Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer. J Urol 2006; 176:972-978. (Pubitemid 44142571)
25. Bhoopalam N, Campbell SC, Moritz T, Broderick WR, Iyer P, Arcenas AG, Van Veldhuizen PJ, Friedman N, Reda D, Warren S, Garewal H: Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk fac tors for bone loss on androgen deprivation therapy. J Urol 2009; 182: 2257-2264.
26. Satoh T, Kimura M, Matsumoto K, Tabata K, Okusa H, Bessho H, Iwamura M, Ishiyama H, Hayakawa K, Baba S: Single infusion of zoledronic acid to prevent androgen deprivation therapy-induced bone loss in men with hormone-naive prostate carcinoma. Cancer 2009; 115:3468-3474.
27. Lipton A: Emerging role of bisphosphonates in the clinic-antitumor activity and prevention of metastasis to bone. Cancer Treat Rev 2008; 34(suppl 1):S25-S30.
28. Weitzman R, Sauter N, Eriksen EF, et al: Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients. Crit Rev Oncol Hematol 2007; 62: 148-152. (Pubitemid 46575276)
29. Mehrotra B: Safety profiles of intravenous bisphosphonates. Semin Oncol 2007; 34 (suppl 4):S24-S27.